Bolt Biotherapeutics, Inc. (BOLT) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2).
Analysis Summary
Bolt Biotherapeutics, Inc. reported revenue of $7.7M in the most recent fiscal year, growing at a 5-year CAGR of 101.6%.
Trailing-twelve-month margins: gross margin 95.7%, operating margin -6.2%, net margin -6.1%.
At the current price of $3.35, BOLT has negative trailing earnings (P/E not meaningful) and an ROE of -125.92%. Market capitalisation stands at $6M.
Balance sheet quality for BOLT: current ratio of 3.6, net cash position of $4.5M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $3.35 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.45 |
| EV / EBITDA | -0.67 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -125.92% |
| Return on Invested Capital | -67.72% |
| Return on Assets | -58.81% |
| Gross Margin | 95.68% |
| Operating Margin | -623.04% |
| Net Margin | -611.47% |
Financial Health
| Debt / Equity | 1.71 |
| Current Ratio | 2.61 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -12.58 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BOLT | Bolt Biotherapeutics, Inc. | $6M | 0.45 | -125.9% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.3B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $131.0B | 29.86 | 6.49 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.6B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $81.3B | 19.15 | 2.61 | 13.8% |
| MRNA | Moderna, Inc. | $62.7B | 1.46 | -39.2% | |
| ARGX | argenx SE | $61.9B | 36.71 | 7.48 | 21.7% |
| RVMD | Revolution Medicines, Inc. | $41.9B | 16.04 | -96.4% |
Price Performance
| 1 month | +11.35% |
| 3 months | -9.02% |
| Year-to-date | -33.64% |
| 1 year | -31.38% |
| 3 years | -83.79% |
| 5 years | -98.81% |
52-Week Range
| 52-week High | $7.20 |
| 52-week Low | $3.13 |
| Avg Volume (90d) | 26K |
Dividend History
| Date | Amount | Yield |
|---|---|---|
| 2014-08-29 | $0.0045 | 0.54% |
| 2014-06-10 | $0.0045 | 0.54% |
| 2014-03-03 | $0.0045 | 0.54% |
| 2013-12-30 | $0.0045 | 0.54% |
| 2013-09-03 | $0.0045 | 0.54% |
| 2013-06-03 | $0.0035 | 0.42% |
| 2013-03-05 | $0.0035 | 0.42% |
| 2012-11-30 | $0.0035 | 0.42% |
| 2012-09-04 | $0.0035 | 0.42% |
| 2012-06-04 | $0.0025 | 0.30% |
Related companies: AEON · CING · CLRB · EVGN · IMNN · INAB · LYRA
Explore sector: Healthcare · Biotechnology
More sections of BOLT: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks